GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Revenue per Share

BCAL Diagnostics (ASX:BDX) Revenue per Share : A$0.00 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Revenue per Share?

BCAL Diagnostics's revenue per share for the six months ended in Dec. 2023 was A$0.00. BCAL Diagnostics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for BCAL Diagnostics's Revenue per Share or its related term are showing as below:

ASX:BDX's 3-Year Revenue Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6.2
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

BCAL Diagnostics Revenue per Share Historical Data

The historical data trend for BCAL Diagnostics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Revenue per Share Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Revenue per Share
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue per Share Get a 7-Day Free Trial - - - - -

Competitive Comparison of BCAL Diagnostics's Revenue per Share

For the Diagnostics & Research subindustry, BCAL Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's PS Ratio falls into.



BCAL Diagnostics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

BCAL Diagnostics's Revenue Per Share for the fiscal year that ended in Jun. 2023 is calculated as

Revenue Per Share (A: Jun. 2023 )=Revenue (A: Jun. 2023 )/Shares Outstanding (Diluted Average) (A: Jun. 2023 )
=0/210.903
=0.00

BCAL Diagnostics's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=0/231.397
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BCAL Diagnostics  (ASX:BDX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


BCAL Diagnostics Revenue per Share Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

BCAL Diagnostics (ASX:BDX) Headlines